https://go.evvnt.com/853526-0?pid=5248 Online event
$1899.00 - $3397.00
Lectures & Conferences, Virtual & Streaming
Marrying unmissable insights from global renal experts, the 1st Rare and Genetic Kidney Disease Drug Development Summit is uniquely positioned to provide you with transformative perspectives from identifying genetic drivers of rare kidney diseases to innovative trial design in small disease populations to accelerate progress of your genetic kidney disease pipeline.
Hear from industry heavyweights including Sanofi Genzyme, Alexion, AstraZeneca, Regulus Therapeutics, Chinook Therapeutics, Ionis Pharmaceuticals, Novartis, Otsuka Pharmaceutical Companies and many more to ignite your entry to the rare and genetic kidney disease landscape and confidently progress from proof of concept to the clinic.
Discover pivotal advances in disease modelling with stem cell-derived kidney organoids, explore opportunities for comprehensive genetic diagnosis and patient stratification, and join the conversation on progressing surrogate biomarkers and endpoints to guide strategic decisions on your pipeline in ADPKD, Alport Syndrome and more.
Get involved to understand why interest in rare and genetic kidney diseases is exploding and keep up to date with the latest opportunities for genetic intervention.
Conference + 2 Workshops | Drug Developer: USD 2797.00,
Conference + 1 Workshop | Drug Developer: USD 2448.00,
Conference Only | Drug Developer: USD 2099.00,
Conference + 2 Workshops | Service and Solution Provider: USD 3397.00,
Conference + 1 Workshop | Service and Solution Provider: USD 2998.00,
Conference Only | Service and Solution Provider: USD 2599.00,
Conference + 2 Workshops | Academic: USD 2497.00,
Conference + 1 Workshop | Academic: USD 2198.00,
Conference Only | Academic: USD 1899.00
Speakers: Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alex Bell, Director Kidney Disease Drug Discovery, Ionis Pharmaceuticals, Ali Hariri, Global Head of Project and Rare Disease, Sanofi Genzyme, Andrew King, Chief Scientific Officer, Chinook Therapeutics, Charlotte Jones-Burton, Vice President, Otsuka Pharmaceutical Companies, Chris Rusconi, Chief Research Officer, Polycystic Kidney Disease Foundation, Christoph Gasteyger, Executive Director, Global Product Team Lead, Alexion, Daniel Gale, St Peter’s Chair of Nephrology, University College London, David Friedman, Co-Director, Harvard University, Denis Drygin, Chief Scientific Officer, Regulus Therapeutics, Domenico Merante, Global Clinical Development TA Lead Nephrology and Orphan Disease Area, Vifor Pharma, Jim McKay, Senior Director, Reata Pharmaceuticals, Jonathan Barratt, The Mayer Professor of Renal Medicine, University of Leicester, Kerry Cooper, Vice President Medical Affairs Renal Cardio, AstraZeneca, Kishor Devalaraja-Narashimha, Associate Director - Cardiovascular and Renal Research, Regeneron, LaToya Coffey, Senior Director, Global Development Team Leader, Otsuka Pharmaceutical Companies, Manish Maski, Head, Global Rare Nephrology Medical Affairs, Sanofi Genzyme, Neil Shusterman, Chief Medical Officer, Palladio Biosciences, Rachel Lennon, Wellcome Senior Research Fellow, University of Manchester, Robert Shepherd, Research and Development Director, Dimerix, Ronald Perrone, Scientific Director - Clinical and Translational Research Center, Professor Tufts University School of Medicine, Shiguang Liu, Clinical Research Director Rare Diseases Nephrology, Sanofi, Stephen Haworth, Chief Medical Officer, XORTX Therapeutics, Tess Harris, Chief Executive Officer, Polycystic Kidney Disease Charity UK, Rasheed Gbadegesin, Professor of Pediatrics and Professor in Medicine, Duke University School of Medicine, Uptal Patel, Head of Clinical Renal and Executive Group Director Early CVRM, AstraZeneca, Wenyan Wang, Senior Clinical Development Director, Novartis